ClinicalTrials.gg
CompletedNCT07615868Updated Oct 27, 2026

A Trial to Compare What the Body Does to Selatogrel and the Effect of Selatogrel in Chinese Adults With Chronic Coronary Syndrome

A Phase 1 interventional study of Selatogrel and Matching placebo in Chronic Coronary Syndrome, sponsored by Viatris Innovation GmbH. Completed at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Viatris Innovation GmbH (part of Viatris Inc.) · Phase 1, Interventional, and Other

Updated Oct 27, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the pharmacokinetics (PK), pharmacodynamics, and tolerability of a single dose of selatogrel in Chinese adults with chronic coronary syndrome.

Pharmacokinetics is the study of the absorption and breakdown of the study drug in the body. Pharmacodynamics is the study of the effect of the study drug on the body.

Researchers will compare selatogrel to a placebo (a look-alike substance that contains no drug).

Participants will stay at the research clinic for 3 or 4 days (2 or 3 nights), during which time they will receive a single dose of selatogrel or placebo. A telephone call for post-trial safety follow-up will be done 30-40 days after the participant leaves the clinic.

02

Conditions studied

  • Chronic Coronary Syndrome
03

In context

Lead sponsor

Viatris Innovation GmbH is the lead sponsor of 24 studies on the registry; 3 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 3 (30%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Chronic coronary syndrome participants defined by the presence of any of the following conditions:

    • History of coronary artery disease with coronary artery stenosis confirmed by a coronary catheterization (at any time prior to Screening) / computed tomography (CT) angiogram ≥ 50%.
    • Previously documented myocardial infarction occurring more than 3 months prior to Screening.
  • Acetylsalicylic acid as mono antiplatelet background therapy stable for at least 1 month prior to Screening.
  • Minimum weight of 50.0 kg at Screening.

Key Exclusion Criteria:

  • Known liver impairment significantly affecting the hepatic function (e.g., ascites, icterus, signs of coagulopathy).
  • End-stage renal failure requiring dialysis.
  • Treatment with another small-molecule or peptide drug within 3 months or 5 × t1/2 (whichever is longer) or with an investigational antibody treatment within 6 months prior to Screening.
  • History of major medical or surgical disorders, which in the opinion of the investigator, are likely to interfere with the metabolism, or excretion of the trial treatment(s) (appendectomy and herniotomy allowed).
  • Concomitant diseases (e.g., advanced liver cirrhosis, mental illness, neurodegenerative disease, terminal , etc.) or conditions (e.g., inability to communicate well with the investigator in the local language, inability to consent) that, in the opinion of the investigator, may prevent subject from complying with study requirements or may be a confounder for the study interpretation.
  • Conditions associated with atherosclerosis:

    • Acute coronary syndrome, percutaneous coronary intervention, Coronary Artery Bypass Grafting, or any intervention for peripheral artery disease within 3 months prior to randomization.
    • Acute ischemic stroke or within 3 months prior to randomization
  • Mitigation of bleeding risks:

    • Active internal bleeding, or medical history of recent (\< 1 month) bleeding disorders or conditions associated with high risk of bleeding (e.g., clotting disturbances, gastrointestinal bleed, hemoptysis, or any history of intracranial bleeding).
    • ≤ 10 g/dL at Screening.
    • Loss of at least 250 mL of blood within 3 months prior to Screening.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Selatogrel

    Study treatment is administered in the morning as a subcutaneous single dose.

    Combination Product: Selatogrel

  • Placebo comparator
    Placebo

    Study treatment is administered in the morning as a subcutaneous single dose.

    Combination Product: Matching placebo

Interventions

  • Combination productSelatogrel

    Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. A single dose of 16 mg selatogrel will be administered as a liquid formulation from a sealed prefilled syringe in an autoinjector forming an integral ready-to-use, single-dose drug delivery system.

  • Combination productMatching placebo

    A single dose of placebo will be administered as a liquid formulation from a sealed prefilled syringe in an autoinjector forming an integral ready-to-use, single-dose drug delivery system.

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration-time curve from zero to time t of the last measured concentration above the limit of quantification (AUC0-t)

    The plasma selatogrel PK parameters will be derived by non compartmental analysis of the concentration-time profiles

    Time frame: Up to 36 hours post-dose

  2. Area under the plasma concentration-time curve from zero to infinity (AUC0-infinity)

    The plasma selatogrel PK parameters will be derived by non compartmental analysis of the concentration-time profiles

    Time frame: Up to 36 hours post-dose

  3. Maximum plasma concentration (Cmax)

    The measured individual plasma concentrations of selatogrel will be used to directly obtain Cmax

    Time frame: Up to 36 hours post-dose

  4. Time to reach maximum plasma concentration (tmax)

    The measured individual plasma concentrations of selatogrel will be used to directly obtain tmax

    Time frame: Up to 36 hours post-dose

  5. Terminal half-life (t1/2)

    The plasma selatogrel PK parameters will be derived by non compartmental analysis of the concentration-time profiles

    Time frame: Up to 36 hours post-dose

07

Study locations

1 site
  • Anzhen Hospital
    Beijing, 100029, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jun 2026 to primary completion in Sep 2026, 2 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Oct 2026 → Sep 2026 and completion Oct 2026 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2026
First posted
May 29, 2026
StartActual
Jun 22, 2026
Primary completionActual
Sep 19, 2026was Oct 2026
CompletionActual
Sep 20, 2026was Oct 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 27, 2026
Primary completion
Oct 2026→Sep 19, 2026 (actual)
Oct 27, 2026
Study completion
Oct 2026→Sep 20, 2026 (actual)
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Recruiting→Completed
    Primary completion Oct 2026→Sep 19, 2026 (now actual)
    Study completion Oct 2026→Sep 20, 2026 (now actual)
    + 2 other changes: contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07615868
Responsible party
Sponsor
First posted
May 29, 2026
Start date
Jun 22, 2026
Primary completion
Sep 19, 2026
Completion
Sep 20, 2026
Last update
Oct 27, 2026

Study contacts

Clinical Trials
study director · Viatris Innovation GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selatogrel

Start the discussion